CSL chief executive Paul Perreault says this year will be “transitional”, tipping a drop in net profit and top-line growth of just 2 to 5 per cent, as the biotech company grapples with tight plasma inventories.
CSL posted a 13 per cent jump in sales and net profit after tax for the year to June 30 – at the top of its 2021 guidance – underpinned by its core immunoglobulin therapies.
Loading...
Carrie LaFrenz is a senior journalist covering retail/consumer goods. She previously covered healthcare/biotech. Carrie has won multiple awards for her journalism including financial journalist of the year from The National Press Club. Connect with Carrie on Twitter. Email Carrie at carrie.lafrenz@afr.com
